BETA

IPO registrations (S-1, F-1) · Registrants

AERIE PHARMACEUTICALS INC

SEC CIK
1337553 · filings on EDGAR ↗
Registration
Form S-1, first filed 2013-09-17, last 2013-10-21; 1 initial registration, 3 amendments
Outcome
Final prospectus filed 2013-10-28; declared effective 2013-10-24
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
4301 EMPEROR BOULEVARD, SUITE 400, Durham, NC 27703
EIN
20-3109565
EDGAR entity type
operating
Insiders and CEO pay
AERIE PHARMACEUTICALS INC on the corporate pages

Offering terms

Proposed price range
$12.00–$14.00 per share (S-1/A filed 2013-10-21)
Final price
$10.00 per share, below the range (424B4 filed 2013-10-28, an initial public offering)
Shares sold
6,720,000
Gross proceeds
$67,200,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol AERI
Lead underwriters
RBC Capital Markets (2,688,000 shares); Stifel (2,688,000 shares)
Syndicate
Canaccord Genuity (672,000); Needham & Company (672,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 8

FiledFormWhat it isName as filedEDGAR
2013-09-17S-1S-1 (registration)AERIE PHARMACEUTICALS INC0001193125-13-369327 ↗
2013-10-03S-1/AS-1/A (amendment)AERIE PHARMACEUTICALS INC0001193125-13-390381 ↗
2013-10-15S-1/AS-1/A (amendment)AERIE PHARMACEUTICALS INC0001193125-13-399020 ↗
2013-10-21S-1/AS-1/A (amendment)AERIE PHARMACEUTICALS INC0001193125-13-405451 ↗
2013-10-24S-1MEFS-1MEF (added securities)AERIE PHARMACEUTICALS INC0001193125-13-410340 ↗
2013-10-24EFFECTEFFECT (declared effective)AERIE PHARMACEUTICALS INC9999999995-13-003069 ↗
2013-10-28424B4424B4 (final prospectus)AERIE PHARMACEUTICALS INC0001193125-13-413566 ↗
2014-11-10EFFECTEFFECT (declared effective)AERIE PHARMACEUTICALS INC9999999995-14-003307 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-10-21S-1/Aregistration statement$12.00–$14.005,250,000-Nasdaq AERI4primary document; range, shares headline, cover names 4document ↗
2013-10-28424B4final prospectus$10.006,720,000$67,200,000Nasdaq AERI4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
ACMP IV LLCTenPercentOwner42013–2014
ACP IV, L.P.TenPercentOwner42013–2014
ANIDO VICENTE JRDirector,OfficerChief Executive Officer252013–2021
BONDERMAN DAVIDOther; TenPercentOwner42013–2014
Buatois EricTenPercentOwner52013–2014
Cagle Gerald D.Director172013–2021
Clarus Lifesciences II, L.P.TenPercentOwner92013–2015
Clarus Ventures II GP, L.P.TenPercentOwner92013–2015
Clarus Ventures II, LLCTenPercentOwner92013–2015
Conway Janet L.Director12013
COULTER JAMES GOther; TenPercentOwner42013–2014
DUYK GEOFFREY MDirector62013–2017
GALAKATOS NICHOLASTenPercentOwner92013–2015
GOLDBERG MURRAY ADirector82013–2020
GRYSKA DAVID WDirector102013–2022
HEALY JAMESTenPercentOwner52013–2014
HENNER DENNISDirector,TenPercentOwner92013–2015
JANNEY DANIELTenPercentOwner42013–2014
Kopczynski Casey C.OfficerChief Scientific Officer342013–2022
LEVY BRIANOfficerChief Medical Officer42013–2015
LIPTAK ROBERTTenPercentOwner92013–2015
Mack David HenryDirector22013
Mehra AnandDirector; Director,TenPercentOwner; TenPercentOwner92013–2015
MITRO THOMAS AOfficerPresident and COO242013–2022
NOHRA GUY PTenPercentOwner42013–2014
POWELL MICHAELTenPercentOwner52013–2014
RUBINO RICHARD JOfficerChief Financial Officer252013–2021
Simon NicholasTenPercentOwner92013–2015
Sofinnova Management VII, L.L.C.TenPercentOwner52013–2014
SOFINNOVA VENTURE PARTNERS VII L PTenPercentOwner52013–2014
STEINMETZ MICHAELTenPercentOwner92013–2015
TPG Group Holdings (SBS) Advisors, Inc.Other; TenPercentOwner42013–2014
WHEELER KURTTenPercentOwner92013–2015
MAZZO JAMES VDirector22014
MCGRAW BENJAMIN F IIIDirector; Director,OfficerInterim Executive Chair132014–2022
Croarkin RichardDirector102015–2022
du Toit MichaelDirector102015–2022
McHugh JulieDirector102015–2022
Foresite Capital Fund III, L.P.TenPercentOwner162016–2020
Foresite Capital Fund II, L.P.TenPercentOwner162016–2020
Foresite Capital Management III, LLCTenPercentOwner162016–2020
Foresite Capital Management II, LLCTenPercentOwner162016–2020
Tananbaum James B.TenPercentOwner202016–2020
LaRocca JohnOfficerGeneral Counsel192018–2022
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)TenPercentOwnerOther22018
Deerfield Mgmt III, L.P.TenPercentOwnerOther22018
Deerfield Mgmt L.P.TenPercentOwnerOther22018
DEERFIELD PARTNERS, L.P.TenPercentOwnerOther22018
Deerfield Private Design Fund III, L.P.TenPercentOwnerOther22018
Deerfield Special Situations Fund, L.P.TenPercentOwnerOther22018
Flynn James ETenPercentOwnerOther22018person page Fuzzy
Foresite Capital Fund IV, L.P.TenPercentOwner122019–2020
Foresite Capital Management IV, LLCTenPercentOwner122019–2020
Hollander DavidOfficerChief R&D Officer62019–2022
McDonnell Peter JDirector52020–2022
Staten ChristopherOfficerInterim CFO22021
MCGINLEY KATHLEENOfficerCHRO & VP, Corp Services22021–2022
Calabrese JeffreyOfficerVice President of Finance62021–2022
KANNAN RAJDirector,OfficerChief Executive Officer42021–2022
Lang Peter FrederickOfficerChief Financial Officer32022

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2014-09-23AERIE PHARMACEUTICALS INCPharmaceuticals$125,000,000$125,000,00051

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationAERIE PHARMACEUTICALS, INC.NCState business registriesname and state
Form D issuerAERIE PHARMACEUTICALS INCNJForm D private offeringsCIK (EXACT)
Paying companyAerie Pharmaceuticals, Inc.NCOpen Payments (drug and device company payments)name and state
SEC filerAERIE PHARMACEUTICALS INCSEC filers (EDGAR)CIK (EXACT)
Trademark ownerAerie Pharmaceuticals, Inc.NCTrademarks (USPTO)name and state
Business registrationAERIE PHARMACEUTICALS, INC.State business registriesEIN (EXACT, as the state registration reports it)
Form 5500 plan sponsorAERIE PHARMACEUTICALS, INC.EIN (EXACT)
Person pageJames E FlynnPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), NC first:

More with this interest.

In other datasets, the same topic (Health) in NC:

Interests: Biological Products, (No Diagnostic Substances) · Health